Metastatic Cancer Clinical Trials

A listing of 63 Metastatic Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Metastatic Cancer

37 - 48 of 63

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 63 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Metastatic Cancer participants are California, Ohio, Michigan and Illinois.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

NCT05566574

Recruiting

The purpose of this study is to test the safety of the study drug, RP-3500 when given in combination with palliative external beam radiotherapy (EBRT) to people who have metastatic solid tumor cancer with a mutation of the ATM gene. The study researchers will do tests to find the highest dose of RP3500 that causes few or mild side effects.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/28/2024

Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites), Basking Ridge, New Jersey +6 locations

Conditions: Solid Tumor, Metastatic Cancer

Learn More ›

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05735080

Recruiting

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 in patients with recurrent advanced/metastatic cancer, including hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer who progressed on a prior cyclin... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/25/2024

Locations: Emory Winship Cancer Institute, Atlanta, Georgia +6 locations

Conditions: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer

Learn More ›

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626

Recruiting

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin is determined, AU-007 plus aldesleukin will also be administered with aveluma... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/22/2024

Locations: START Midwest, Grand Rapids, Michigan +12 locations

Conditions: Advanced Solid Tumor, Metastatic Cancer

Learn More ›

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

NCT05082610

Recruiting

This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or without pembrolizumab KEYTRUDA®, in patients with advanced solid tumors (i.e., locally advanced and unresectable, or metastatic).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/21/2024

Locations: The City of Hope National Medical Center, Duarte, California +5 locations

Conditions: Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor

Learn More ›

PRE-I-SPY Phase I/Ib Oncology Platform Program

NCT05868226

Recruiting

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/02/2024

Locations: The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama +5 locations

Conditions: HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer

Learn More ›

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

NCT05789589

Recruiting

To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/30/2024

Locations: Miami Cancer Institute at Baptist Health, Inc., Miami, Florida

Conditions: Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult

Learn More ›

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

NCT03785249

Recruiting

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/18/2024

Locations: ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama +213 locations

ONeal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama

Alaska Oncology and Hematology, Anchorage, Alaska

Mayo Clinic Arizona - Phoenix Campus, Phoenix, Arizona

Local Institution - 001-807, Scottsdale, Arizona

Local Institution - 001-873-A, Tucson, Arizona

USOR - Arizona Oncology - Tucson - Rudasill, Tucson, Arizona

Local Institution - 001-840-B, Bellflower, California

Beverly Hills Cancer Center, Beverly Hills, California

City of Hope - Duarte (Main Campus), Duarte, California

Local Institution - 001-850-K, Dublin, California

Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton, Fullerton, California

Local Institution - 001-840-C, Harbor City, California

University of California San Diego Moores Cancer Center, La Jolla, California

TRIO - Cancer and Blood Specialty Clinic, Los Alamitos, California

Southern California Permanente Medical Group - Los Angeles Medical Center, Los Angeles, California

Valkyrie Clinical Trials, Los Angeles, California

Hoag Memorial Hospital Presbyterian - Newport Beach, Newport Beach, California

Local Institution - 001-850-B, Oakland, California

University of California Irvine Medical Center, Orange, California

Local Institution - 001-850-C, Roseville, California

Local Institution - 001-850-J, Sacramento, California

Local Institution - 001-850-D, Sacramento, California

California Cancer Associates for Research and Excellence (cCARE) - San Diego 4S Ranch, San Diego, California

Local Institution - 001-840-A, San Diego, California

Local Institution - 001-850-H, San Francisco, California

Local Institution - 001-850-E, San Francisco, California

Local Institution - 001-850-F, San Jose, California

Local Institution - 001-850-A, San Leandro, California

Ridley - Tree Cancer Center - Santa Barbara, Santa Barbara, California

Local Institution - 001-850-I, Santa Clara, California

Local Institution - 001-884-A, Solvang, California

Kaiser Permanente - Vallejo Medical Center, Vallejo, California

Local Institution - 001-850-G, Walnut Creek, California

USOR - Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado

UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, Colorado

Local Institution - 001-872-H, Boulder, Colorado

Local Institution - 001-872-E, Colorado Springs, Colorado

Local Institution - 001-872-B, Denver, Colorado

Local Institution - 001-951 - A, Denver, Colorado

Local Institution - 001-951 - B, Denver, Colorado

Cancer Centers of Colorado - St. Marys Regional Hospital, Grand Junction, Colorado

SCL Health - Saint Joseph Hospital Cancer Center, Lafayette, Colorado

Local Institution - 001-872-A, Lakewood, Colorado

Local Institution - 001-872-D, Littleton, Colorado

Local Institution - 001-872-K, Lone Tree, Colorado

Local Institution - 001-872-C, Longmont, Colorado

Local Institution - 001-872-J, Parker, Colorado

Local Institution - 001-872-F, Pueblo, Colorado

Local Institution - 001-872-G, Pueblo, Colorado

Local Institution - 001-872-I, Thornton, Colorado

Yale Cancer Center, New Haven, Connecticut

USOR - Medical Oncology Hematology Consultants, Newark, Delaware

Local Institution - 001-929i, Altamonte Springs, Florida

Boca Raton Clinical Research Associates, Inc., Boca Raton, Florida

Local Institution - 001-929c, Brandon, Florida

Local Institution - 001-929g, Clearwater, Florida

Local Institution - 001-926b, Daytona Beach, Florida

SCRI - Florida Cancer Specialists - South Region Research Office, Fort Myers, Florida

Local Institution - 001-929b, Gainesville, Florida

Mayo Clinic - Jacksonville, Jacksonville, Florida

Local Institution - 001-929m, Lady Lake, Florida

Local Institution - 001-929e, Largo, Florida

Local Institution - 001-929n, Lecanto, Florida

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida

Miami Cancer Institute, Miami, Florida

Florida Cancer Affiliates - Ocala - Main, Ocala, Florida

Local Institution - 001-929p, Ocala, Florida

Local Institution - 001-929j, Orange City, Florida

Mid Florida Cancer Centers - Orange City, Orange City, Florida

Local Institution - 001-929l, Orlando, Florida

Woodlands Medical Specialists, Pensacola, Florida

Local Institution - 001-929a, Saint Petersburg, Florida

SCRI - Florida Cancer Specialists - North Region Research Office, Saint Petersburg, Florida

Local Institution - 001-929h, Spring Hill, Florida

Local Institution - 001-926d, Stuart, Florida

Local Institution - 001-929d, Tampa, Florida

Local Institution - 001-929k, Tavares, Florida

Local Institution - 001-929f, Trinity, Florida

Local Institution - 001-926c, Vero Beach, Florida

Local Institution - 001-926a, Wellington, Florida

SCRI - Florida Cancer Specialists - East Region Research Office, West Palm Beach, Florida

Local Institution - 001-929o, Winter Park, Florida

University Cancer & Blood Center (UCBC) - Athens, Athens, Georgia

Local Institution - 001-835-C, Austell, Georgia

Local Institution - 001-835-E, Austell, Georgia

Local Institution - 001-835-D, Carrollton, Georgia

Local Institution - 001-835-F, Carrollton, Georgia

Local Institution - 001-835-A, Cartersville, Georgia

Local Institution - 001-835-B, Douglasville, Georgia

Northwest Georgia Oncology Centers Wellstar - Marietta, Marietta, Georgia

Affiliated Oncologists - Millenium Medical Center - Chicago Ridge, Chicago Ridge, Illinois

Local Institution - 001-828, Chicago, Illinois

USOR - Illinois Cancer Specialists - Niles, Niles, Illinois

Memorial Hospital, South Bend, Indiana

University of Iowa, Iowa City, Iowa

University of Kansas Medical Center, Westwood, Kansas

University of Kentucky, Lexington, Kentucky

SCRI - Hematology Oncology Clinic - Baton Rouge, Baton Rouge, Louisiana

MaineHealth Cancer Care - Biddeford, Biddeford, Maine

Local Institution - 001-881-B, Brandywine, Maryland

Maryland Oncology Hematology - Columbia, Columbia, Maryland

Local Institution - 001-881-A, Silver Spring, Maryland

Dana-Farber Cancer Institute, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Henry Ford Health System, Detroit, Michigan

Local Institution - 001-842-A, Farmington Hills, Michigan

Local Institution - 001-838-F, Coon Rapids, Minnesota

Local Institution - 001-838-E, Edina, Minnesota

Local Institution - 001-875 - D, Edina, Minnesota

Local Institution - 001-838-D, Maplewood, Minnesota

Local Institution - 001-875 - A, Maplewood, Minnesota

Local Institution - 001-838-C, Minneapolis, Minnesota

USOR - Minnesota Oncology - Minneapolis Clinic, Minneapolis, Minnesota

Local Institution - 001-838-G, Minneapolis, Minnesota

Local Institution - 001-822-A, Minneapolis, Minnesota

Masonic Cancer Center, Minneapolis, Minnesota

Mayo Clinic - Rochester, Rochester, Minnesota

Metro-Minnesota Community Oncology Research Consortium (MMCORC), Saint Louis Park, Minnesota

Local Institution - 001-838-B, Saint Louis Park, Minnesota

Local Institution - 001-838-A, Saint Paul, Minnesota

Local Institution - 001-875 - B, Saint Paul, Minnesota

Local Institution - 001-875 - C, Woodbury, Minnesota

Central Care Cancer Center - Bolivar, Bolivar, Missouri

Goldschmidt Cancer Center, Jefferson City, Missouri

Sisters of Charity of Leavenworth Health St. Marys, Billings, Montana

Local Institution - 001-544B, Omaha, Nebraska

Methodist Estabrook Cancer Center, Omaha, Nebraska

Local Institution - 001-544A, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Local Institution - 001-860A, Henderson, Nevada

Local Institution - 001-860C, Henderson, Nevada

Local Institution - 001-860B, Henderson, Nevada

USOR - Comprehensive Cancer Centers of Nevada - Southeast Henderson, Henderson, Nevada

Local Institution - 001-860E, Las Vegas, Nevada

Local Institution - 001-860D, Las Vegas, Nevada

Local Institution - 001-860F, Las Vegas, Nevada

New York Oncology Hematology - Albany Medical Center, Albany, New York

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Local Institution - 001-832, Lake Success, New York

Perlmutter Cancer Center - 34th Street, New York, New York

Local Institution - 001-583, New York, New York

Memorial Sloan Kettering Cancer Center - New York, New York, New York

University of North Carolina Hospitals, Chapel Hill, North Carolina

FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina

The Christ Hospital, Cincinnati, Ohio

University of Cincinnati Health Barrett Cancer Center, Cincinnati, Ohio

Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Local Institution - 001-833 - H, Columbus, Ohio

Local Institution - 001-833 - C, Columbus, Ohio

Local Institution - 001-833 - J, Columbus, Ohio

Local Institution - 001-833 - A, Columbus, Ohio

Local Institution - 001-833 - F, Columbus, Ohio

The Ohio State University College of Medicine, Columbus, Ohio

Local Institution - 001-833 - D, Columbus, Ohio

Local Institution - 001-833 - I, Columbus, Ohio

SCRI - Mark H. Zangmeister Cancer Center, Columbus, Ohio

Local Institution - 001-833 - B, Columbus, Ohio

Local Institution - 001-833 - G, Columbus, Ohio

Local Institution - 001-833 - E, Gahanna, Ohio

Kettering Health Cancer Center - Main Campus, Kettering, Ohio

Local Institution - 001-836-A, Kettering, Ohio

Cancer Centers of Southwest Oklahoma - Leah M. Fitch Cancer Center, Lawton, Oklahoma

Local Institution - 001-580, Oklahoma City, Oklahoma

Local Institution - 001-584, Tulsa, Oklahoma

Local Institution - 001-586-A, Bend, Oregon

St. Charles Health System, Bend, Oregon

Willamette Valley Cancer Institute and Research Center - Eugene, Eugene, Oregon

Lehigh Valley Physician Group Hematology Oncology, Allentown, Pennsylvania

Local Institution - 001-837-A, Bethlehem, Pennsylvania

Penn State Cancer Institute, Hershey, Pennsylvania

USOR - Alliance Cancer Specialists - Media (Cancer Center at Riddle Memorial Hospital), Media, Pennsylvania

USOR - Charleston Hematology Oncology Associates, Charleston, South Carolina

Medical University of South Carolina, Charleston, South Carolina

Local Institution - 001-801-G, Gallatin, Tennessee

Local Institution - 001-801-A, Hendersonville, Tennessee

Local Institution - 001-801-D, Hermitage, Tennessee

Local Institution - 001-801-F, Murfreesboro, Tennessee

Local Institution - 001-801-B, Nashville, Tennessee

Tennessee Oncology - Nashville - Centennial Clinic - Medical Oncology, Nashville, Tennessee

Local Institution - 001-801-E, Nashville, Tennessee

Local Institution - 001-801-C, Nashville, Tennessee

Local Institution - 001-888-B, Arlington, Texas

USOR - Texas Oncology Dallas Fort Worth West (DFWW) - Arlington South, Arlington, Texas

USOR - Texas Oncology - Austin Central, Austin, Texas

Local Institution - 001-848a, Conroe, Texas

Mary Crowley Cancer Research - Medical City Hospital, Dallas, Texas

USOR - Texas Oncology - Dallas Fort Worth (DFW) - Presbyterian Cancer Center Dallas, Dallas, Texas

USOR - Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

USOR - Texas Oncology Northeast Texas - Denison, Denison, Texas

Texas Oncology - Dallas Fort Worth (DFW) - Fort Worth, Fort Worth, Texas

Oncology Consultants - Texas Medical Center, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Local Institution - 001-935A, Houston, Texas

Local Institution - 001-999, Irving, Texas

Local Institution - 001-935D, Kingwood, Texas

Lumi Research, Kingwood, Texas

USOR - Texas Oncology - Midland Allison Cancer Center, Midland, Texas

START Center for Cancer Care, San Antonio, Texas

Local Institution - 001-935B, Shenandoah, Texas

Local Institution - 001-935C, Spring, Texas

Texas Oncology - Sugar Land, Sugar Land, Texas

Local Institution - 001-935E, Tomball, Texas

Texas Oncology - Northeast Texas Cancer and Research Institute - Tyler, Tyler, Texas

Texas Oncology - Waco, Waco, Texas

Local Institution - 001-919, Fairfax, Virginia

NEXT Virginia, Fairfax, Virginia

Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia

USOR - Virginia Oncology Associates - Newport News, Newport News, Virginia

Local Institution - 001-882-A, Norfolk, Virginia

Virginia Cancer Institute - West End, Richmond, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver, Washington

University Wisconsin Carbone Cancer Center, Madison, Wisconsin

PanOncology Trials - Rio Piedras Medical Center, San Juan, Not set

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease

Learn More ›

A Phase 2 Open Label Study of BA3021 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05271604

Recruiting

This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/10/2024

Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +7 locations

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck

Learn More ›

Biomarkers of Immune-Related Toxicity

NCT03409016

Recruiting

This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

09/10/2024

Locations: University of Colorado Denver, Aurora, Colorado

Conditions: Cancer, Metastatic Cancer

Learn More ›

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

NCT05036681

Recruiting

It's propose this pilot phase 2 study to explore the combination therapy of futibatinib with pembrolizumab in patients with metastatic microsatellite stable (MSS) endometrial carcinoma to provide a well-tolerated regimen for durable responses.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/07/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma

Learn More ›

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

NCT04295863

Recruiting

A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/30/2024

Locations: University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois +1 locations

Conditions: Metastatic Cancer

Learn More ›

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

NCT05502315

Recruiting

This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).

Gender:

MALE

Ages:

18 years and above

Trial Updated:

07/16/2024

Locations: University of California San Diego, La Jolla, California +3 locations

Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer

Learn More ›

37 - 48 of 63